Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

- HGS reacquires GSK rights to TRAIL receptor antibodies in return for

reduction in Syncria(R) royalties -

- HGS-ETR1 Phase 2 development program expands -

ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has reacquired rights to the TRAIL receptor antibodies HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab) from GlaxoSmithKline (GSK), in return for a reduction in royalties due to HGS if Syncria(R) (albiglutide) is commercialized. HGS is developing its TRAIL receptor antibodies for the treatment of a broad range of cancers, and announced today that it plans to initiate its third randomized Phase 2 chemotherapy combination trial of HGS-ETR1 by mid-2008 in patients with hepatocellular cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

"As our Phase 3 products near commercialization, we are investing strategically to bring our next products forward," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "We are building our oncology portfolio around our leading expertise in the apoptosis pathway. We have added IAP inhibitors, which are highly complementary to our TRAIL receptor antibodies. We have initiated new chemotherapy combination trials of HGS-ETR1, and we have now reacquired the rights to our TRAIL receptor antibodies."

The GSK rights to the TRAIL receptor antibodies resulted from a June 1996 agreement under which HGS granted a 50/50 co-development and co-promotion option to GSK for certain human therapeutic products that complete Phase 2a clinical trials. In exchange for reacquiring the rig
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... “Nature has developed, very cleverly, some ... desire in optical design,” said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we’ll ... in San Diego in August during a conference called ... chaired by Shaw and Rongguang Liang of the University ...
(Date:9/16/2014)... From cell phones to cars and flashlights, batteries ... and technology companies constantly are seeking ways to ... first time using a water-based solution, researchers at ... and more efficient nuclear battery that could be ... energy source in automobiles and also in complicated ...
(Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors has ... CIRTEC. , “I am delighted to be joining ... Brian Highley. “The company has made great strides improving ... over the past two years. The goal now is ... expand the services Cirtec offers its medical device customers.” ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the ... and products to hospitals, physician office laboratories and ... effective October 1, 2014, it will serve as ... hospital market segments and as a semi-exclusive sales ... 48 contiguous United States . ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Merrimack Pharmaceuticals, Inc. announced today that it ... therapeutic consisting of a mixture of three human ... irinotecan, at the 14th World Conference on Lung ... in Amsterdam, The Netherlands. (Logo: ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... approved its Los Angeles cancer immunotherapy manufacturing facility, allowing ... PROVENGE ® (sipuleucel-T) across the U.S. to help ... symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.   ...
... Branch Fund: A Thisbe and Noah Scott Legacy, an ... announced its first funding award to Kevin Eggan, Ph.D., ... Harvard University.  The award will support Dr. Eggan,s ongoing ... affect it.  Dr. Eggan is a leading researcher in ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... The world,s leading conservation organizations have joined together to fight ... gorilla ( Gorilla beringei graueri ). Found only in ... of Congo (DRC), Grauer,s gorilla is not only the largest ... in the world. With their entire range consumed in ...
... and walked on two legs is considered to be one of ... to the far ends of the earth and the wonderful ... walk the way we walk. In the latest such search, ... have taken a closer look at bipedal kangaroos and wallabies and ...
... PA, March 13, 2013 Many Canadians are concerned ... sodium intake through a variety of measures, including lowering ... a national survey. The top barriers to limiting sodium ... processed foods and lower sodium restaurant menu options. ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3It's all in the way we move 2Canadians support interventions to reduce dietary salt 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: